<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237157</url>
  </required_header>
  <id_info>
    <org_study_id>RR1</org_study_id>
    <nct_id>NCT02237157</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer</brief_title>
  <official_title>A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenovoRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenovoRx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the&#xD;
      pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients diagnosed with unresectable pancreatic cancer who may or may not have had prior&#xD;
      chemotherapy or radiation therapy may be eligible to enroll in this dose escalation study to&#xD;
      determine the maximum tolerated dose of gemcitabine to be delivered locally to the pancreatic&#xD;
      tumors using the RenovoCath R120 catheter. Patients enrolled may receive up to 8&#xD;
      catheterizations for delivering gemcitabine directly to the pancreatic tumors starting at a&#xD;
      reduced dose( 1/4 of standard i.v. gemcitabine dose), then every two doses, increase the dose&#xD;
      by 25% if there are no toxicities up to a maximum dose of 1000 mg/m2. There are four cycles,&#xD;
      with two doses per cycle. Imaging studies will be conducted as well as assessment for&#xD;
      standard, myelosuppresive and gastric toxicities will be assessed. Pain will also be measured&#xD;
      throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects receive a gradual increase of drug dose, until the full systemic dose is administered. Cycle 1: 250mg/m2. Cycle 2: 500mg/m2. Cycle 3: 750mg/m2. Cycle 4: 1000mg/m2.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas</measure>
    <time_frame>1 week post treatment</time_frame>
    <description>Maximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter.&#xD;
One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CA19-9 Tumor Reduction</measure>
    <time_frame>1 week after treatment</time_frame>
    <description>Measurements of CA19-9 tumor marker are measured pre-treatment and at various time points (starting with one week) post treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine, Local Delivery (Dose 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine, Local Delivery (Dose 2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine, Local Delivery (Dose 3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine, Local Delivery (Dose 4)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, local delivery</intervention_name>
    <description>Intra-arterial targeted drug delivery</description>
    <arm_group_label>Gemcitabine, Local Delivery (Dose 1)</arm_group_label>
    <arm_group_label>Gemcitabine, Local Delivery (Dose 2)</arm_group_label>
    <arm_group_label>Gemcitabine, Local Delivery (Dose 3)</arm_group_label>
    <arm_group_label>Gemcitabine, Local Delivery (Dose 4)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects will be eligible to participate in the study if all of the following criteria are&#xD;
        met:&#xD;
&#xD;
          1. Males and female subjects 18 years of age and older.&#xD;
&#xD;
          2. Subjects with locally advanced unresectable adenocarcinoma (cytological or histologic&#xD;
             proof required) of the pancreas.. Patients with islet cell tumors are not eligible.&#xD;
&#xD;
          3. No clinical evidence of distant metastases, excluding single liver metastasis and&#xD;
             local lymph node involvement. Patients with more than a single liver metastasis and/or&#xD;
             other metastases who have already failed systemic chemotherapy and/or are on a break&#xD;
             from systemic chemotherapy who are not surgical candidates can also qualify for this&#xD;
             study.&#xD;
&#xD;
          4. Karnofsky Performance Status (KPS) &gt;60.&#xD;
&#xD;
          5. Adequate renal, and bone marrow function described as:&#xD;
&#xD;
               1. Leukocytes ≥ 3,000/uL&#xD;
&#xD;
               2. Absolute neutrophil count ≥ 1,500/uL&#xD;
&#xD;
               3. Platelets ≥100,000/uL&#xD;
&#xD;
               4. Serum creatinine ≥2.0 mg/dL. Creatinine less than or equal to 1.5 mg/dL or&#xD;
                  creatinine clearance greater than 40 mL/min/1.73 m2 for patients with creatinine&#xD;
                  levels above institutional normal, as calculated by the Cockcroft Gault formula.&#xD;
&#xD;
               5. Hemoglobin ≥8.5 g/dL (may be receiving supportive therapy)&#xD;
&#xD;
               6. PT/PTT (WNL)&#xD;
&#xD;
          6. Adequate Hepatic function (endoscopic or percutaneous drainage as needed) described&#xD;
             as:&#xD;
&#xD;
               1. Total bilirubin ≤3 times UNL (less than or equal to 2 mg/dL)&#xD;
&#xD;
               2. AST (SGOT)/ALT (SGPT) ≤ 5 times ULN or ≤5 times ULN in the setting of liver&#xD;
                  metastases.&#xD;
&#xD;
               3. Lipase and Amylase within normal limits.&#xD;
&#xD;
          7. Capable of understanding the purpose and risks of the study and willing to provide&#xD;
             written informed consent and to comply with the procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from participation in the study if any of the following criteria&#xD;
        are met:&#xD;
&#xD;
          1. Have a known sensitivity to gemcitabine.&#xD;
&#xD;
          2. Identification of metastatic disease, with the exception of single liver metastases or&#xD;
             local lymph node involvement. Patients with more than a single liver metastasis and/or&#xD;
             other metastases who have already failed systemic chemotherapy and/or are on a break&#xD;
             from systemic chemotherapy who are not surgical candidates can also qualify for this&#xD;
             study.&#xD;
&#xD;
          3. Evidence of coagulopathy.&#xD;
&#xD;
          4. Inability or unwillingness to comply with study procedures and/or follow-up&#xD;
             procedures.&#xD;
&#xD;
          5. Evidence of infection or other coexisting medical condition, which in the opinion of&#xD;
             the investigator would preclude administration of gemcitabine.&#xD;
&#xD;
          6. Patients with uncontrolled congestive heart failure, unstable angina and myocardial&#xD;
             infarction within 3 months.&#xD;
&#xD;
          7. Female patient who is pregnant, nursing or planning on becoming pregnant.&#xD;
&#xD;
          8. Current enrollment and participation in another clinical study or prior exposure to an&#xD;
             investigational agent within 12 weeks or 5 half-lives (whichever is longer) of&#xD;
             anticipated dosing on Day 1 of this study.&#xD;
&#xD;
          9. Have known brain metastases.&#xD;
&#xD;
         10. Have had any major surgery within four weeks of enrollment.&#xD;
&#xD;
         11. Have any clinically detectable ascites.&#xD;
&#xD;
         12. Have uncontrolled concomitant illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac&#xD;
             arrhythmia.&#xD;
&#xD;
         13. Have serious medical or psychiatric illness that could, in the Investigator's opinion,&#xD;
             potentially interfere with the completion of treatment according to this protocol.&#xD;
&#xD;
         14. Other invasive malignancies within the past 3 years (with the exception of&#xD;
             non-melanoma skin cancers, non-invasive bladder cancer or prostate cancer) not&#xD;
             approved by the Medical Monitor (contact MM in event of prior diagnosis with&#xD;
             malignancy to discuss enrollment status).&#xD;
&#xD;
         15. Have had any chemotherapy or systemic corticosteroids within 2 weeks of study entry.&#xD;
&#xD;
         16. Have acquired, hereditary or congenital immunodeficiency's including cellular&#xD;
             immunodeficiencies, hypogammaglobulinemia and dysgammaglobulinemia or hepatitis.&#xD;
&#xD;
         17. Have a prior history of a documented hemolytic event.&#xD;
&#xD;
         18. Is HIV-positive or Hepatitis positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiali Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>El Camino Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>El Camino Hospital, Oncology</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 8, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <results_first_submitted>December 6, 2018</results_first_submitted>
  <results_first_submitted_qc>April 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2021</results_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>unresectable</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>device</keyword>
  <keyword>local delivery</keyword>
  <keyword>chemoembolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects who complete a cycle (&quot;arm&quot;/&quot;period&quot;) then proceed to receive the next higher dose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine, Local Delivery (Dose 1)</title>
          <description>Gemcitabine; 1 cycles, two doses per cycle; 250mg/m2 dose&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
        <group group_id="P2">
          <title>Gemcitabine, Local Delivery (Dose 2)</title>
          <description>Gemcitabine; 1 cycles, two doses per cycle; 500mg/m2 dose&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
        <group group_id="P3">
          <title>Gemcitabine, Local Delivery (Dose 3)</title>
          <description>Gemcitabine; 1 cycles, two doses per cycle; 750mg/m2 dose&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
        <group group_id="P4">
          <title>Gemcitabine, Local Delivery (Dose 4)</title>
          <description>Gemcitabine; 1 cycles, two doses per cycle; 1000mg/m2 dose&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Gemcitabine, Local Delivery (Dose 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Gemcitabine, Local Delivery (Dose 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Gemcitabine, Local Delivery (Dose 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Gemcitabine, Local Delivery (Dose 4)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine, Local Delivery</title>
          <description>Gemcitabine; 4 cycles, two doses per cycle; dose escalation&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas</title>
        <description>Maximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter.&#xD;
One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.</description>
        <time_frame>1 week post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine, Local Delivery</title>
            <description>Gemcitabine; 4 cycles, two doses per cycle; dose escalation&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas</title>
          <description>Maximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter.&#xD;
One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.</description>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CA19-9 Tumor Reduction</title>
        <description>Measurements of CA19-9 tumor marker are measured pre-treatment and at various time points (starting with one week) post treatment.</description>
        <time_frame>1 week after treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the treatment period, an average of 2.5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine, Local Delivery (Dose 1)</title>
          <description>Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
        <group group_id="E2">
          <title>Gemcitabine, Local Delivery (Dose 2)</title>
          <description>Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
        <group group_id="E3">
          <title>Gemcitabine, Local Delivery (Dose 3)</title>
          <description>Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
        <group group_id="E4">
          <title>Gemcitabine, Local Delivery (Dose 4)</title>
          <description>Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose&#xD;
Gemcitabine, local delivery: Intra-arterial targeted drug delivery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain - Abdominal (NOS)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Duodenal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Intraoperative Arterial Injury / Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Intraoperative Arterial Injury - Lower Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intraoperative arterial injury - lower extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Intraoperative arterial injury - pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Median arcuate ligament syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles Li</name_or_title>
      <organization>RenovoRx</organization>
      <phone>(650) 284-4433</phone>
      <email>charles@renovorx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

